Frankfurt - Delayed Quote EUR

Sol-Gel Technologies Ltd. (4SG.F)

0.5900

+0.1460

+(32.88%)

At close: April 23 at 12:59:42 PM GMT+2

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210

GlobeNewswire 6 days ago

SLGL

MAYNF
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.

Zacks last month

SLGL
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 2 months ago

SLGL
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know

SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 4 months ago

SLGL
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s ("Nasdaq") minimum bid pric

GlobeNewswire 4 months ago

SLGL
Sol-Gel Technologies Third Quarter 2024 Earnings: Beats Expectations

Sol-Gel Technologies ( NASDAQ:SLGL ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.36m (up by US$5.15m...

Simply Wall St. 5 months ago

SLGL
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of 92.31% and 99.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

SLGL

PHR
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-6

GlobeNewswire 5 months ago

SLGL
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 7 months ago

SLGL
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy

SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 7 months ago

SLGL
Sol-Gel Technologies Second Quarter 2024 Earnings: Beats Expectations

Sol-Gel Technologies ( NASDAQ:SLGL ) Second Quarter 2024 Results Key Financial Results Revenue: US$5.43m (up by...

Simply Wall St. 7 months ago

SLGL
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoingSol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug

GlobeNewswire 8 months ago

SLGL
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of 135% and 414.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 8 months ago

SLGL
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoingSol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug p

GlobeNewswire 8 months ago

SLGL
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

Sol-Gel to receive upfront and regulatory milestone payments totaling in up to low 7-digit USD and either fixed transfer sale price or low double-digit royalties from net sales; payments are backed by commitments to minimum annual salesNESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syn

GlobeNewswire 8 months ago

SLGL
Sol-Gel Technologies Announces Management Realignment

NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that the Chief Executive Officer, Dr. Alon Seri-Levy, has recently advised the Sol-Gel Board of Directors of his desire to step dow

GlobeNewswire 9 months ago

SLGL
We're A Little Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 10 months ago

SLGL
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it received a notification letter on May 21 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, stating t

GlobeNewswire 10 months ago

SLGL
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 10 months ago

SLGL

ACB
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million.Sol-Gel recently initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease.Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric p

GlobeNewswire 10 months ago

SLGL

Performance Overview

Return	4SG.F	S&P 500 (^GSPC)
YTD	-41.00%	-8.60%
1-Year	-29.76%	+6.02%
3-Year	-90.78%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sol-Gel Technologies Ltd. (4SG.F)

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

Sol-Gel Technologies Third Quarter 2024 Earnings: Beats Expectations

Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy

Sol-Gel Technologies Second Quarter 2024 Earnings: Beats Expectations

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

Sol-Gel Technologies Announces Management Realignment

We're A Little Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate

Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Performance Overview